Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: In vitro and in vivo studies

Exploitation of amaranth oil fractions enriched in squalene for dual delivery of hydrophilic and lipophilic actives

“…Usually, in the treatment of various diseases it is not sufficient to use highly active drugs, the effectiveness of any active being mainly dependent upon its delivery in an appropriate concentration to target cells and tissue (Borrelli et al, 2014). A great challenge comes from the difficulty to design functional delivery systems which combine low toxicity, lack of immunogenicity and biodegradability, does not accumulate in cells or tissues, and could also bring supplementary biological effects (Jyoti et al, 2015;Lacatusu et al, 2012).…”

The Noscapine Chronicle: A Pharmaco‐Historic Biography of the Opiate Alkaloid Family and its Clinical Applications

“…84 An inhalable rapid-release nanostructured lipid particle species of 9-bromonoscapine (9-Br-Nos-RR-NLP) was synthesized since this noscapinoid alters tubulin polymerization better than the parent compound in non-small cell lung cancer cells. 85 These 9-Br-Nos-RR-NLPs showed enhanced cytotoxicity, apoptosis, and cellular uptake in A549 non-small cell lung cancer cells according to Jyoti et al They found the IC 50 value to be less than that of the nonrapid release form, 9-Br-Nos-NLP, and 9-Br-Nos suspension. 85 Novel 9-alkyl and 9-arylnoscapine derivatives have been synthesized and showed similar cytotoxic potency in comparison to 9-Br-Nos.…”

“…These modified bromonoscapinoids exhibited a more potent therapeutic index by lowering the IC50 value . An inhalable rapid‐release nanostructured lipid particle species of 9‐bromonoscapine (9‐Br‐Nos‐RR‐NLP) was synthesized since this noscapinoid alters tubulin polymerization better than the parent compound in non‐small cell lung cancer cells . These 9‐Br‐Nos‐RR‐NLPs showed enhanced cytotoxicity, apoptosis, and cellular uptake in A549 non‐small cell lung cancer cells according to Jyoti et al.…”

Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery

“…Targeted delivery of the pharmaceuticals has been well established by various researchers via both systemic and respiratory routes for an assortment of malignant lung disorders including small cell lung cancer (SCLC) utilizing active monoclonal antibody targeting approach for both therapeutic efficacy and for diagnostic visualization [93][94][95][96]. At the same time, several groups have studied gene targeting as a treatment approach for cystic fibrosis [97][98][99].…”